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BACKGROUND

The use of adjuvant chemotherapy in patients with breast cancer may be guided by
clinicopathological factors and a score based on a 21-gene assay to determine the risk
of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known.
METHODS

We performed a prospective trial involving 9427 women with hormone-receptor–positive, human epidermal growth factor receptor 2–negative, axillary node–negative
breast cancer, in whom an assay of 21 genes had been performed, and we classified
the clinical risk of recurrence of breast cancer as low or high on the basis of the tumor
size and histologic grade. The effect of clinical risk was evaluated by calculating hazard
ratios for distant recurrence with the use of Cox proportional-hazards models. The
initial endocrine therapy was tamoxifen alone in the majority of the premenopausal
women who were 50 years of age or younger.
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RESULTS

The level of clinical risk was prognostic of distant recurrence in women with an intermediate 21-gene recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores indicating a worse prognosis or a greater potential benefit from chemotherapy) who were
randomly assigned to endocrine therapy (hazard ratio for the comparison of high vs. low
clinical risk, 2.73; 95% confidence interval [CI], 1.93 to 3.87) or to chemotherapy plus
endocrine (chemoendocrine) therapy (hazard ratio, 2.41; 95% CI, 1.66 to 3.48) and in
women with a high recurrence score (a score of 26 to 100), all of whom were assigned to
chemoendocrine therapy (hazard ratio, 3.17; 95% CI, 1.94 to 5.19). Among women who
were 50 years of age or younger who had received endocrine therapy alone, the estimated
(±SE) rate of distant recurrence at 9 years was less than 5% (≤1.8±0.9%) with a low recurrence score (a score of 0 to 10), irrespective of clinical risk, and 4.7±1.0% with an intermediate recurrence score and low clinical risk. In this age group, the estimated distant
recurrence at 9 years exceeded 10% among women with a high clinical risk and an intermediate recurrence score who received endocrine therapy alone (12.3±2.4%) and among
those with a high recurrence score who received chemoendocrine therapy (15.2±3.3%).
CONCLUSIONS

Clinical-risk stratification provided prognostic information that, when added to the
21-gene recurrence score, could be used to identify premenopausal women who
could benefit from more effective therapy. (Funded by the National Cancer Institute
and others; ClinicalTrials.gov number, NCT00310180.)
n engl j med 380;25
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C

linicopathological features, including tumor size, histologic grade, and
the presence of axillary lymph-node metastases, provide prognostic information about disease recurrence in women who have localized
breast cancer after surgery, but these features
have not been shown to be predictive of benefit
from adjuvant chemotherapy.1 In women with
hormone-receptor–positive, human epidermal
growth factor receptor 2 (HER2)–negative early
breast cancer, the 21-gene recurrence-score assay
provides prognostic information that is independent of clinicopathological features,2 and a high
score (on a scale of 0 to 100) indicates a higher
rate of distant recurrence and is predictive of
chemotherapy benefit. A high score has been defined as 31 or higher on the basis of the prospective
validation National Surgical Adjuvant Breast and
Bowel Project (NSABP) B20 and Southwest Oncology Group S8814 trial cohorts3,4 or 26 or higher
on the basis of the NSABP B20 trial cohort.5,6
The prospective Trial Assigning Individualized
Options for Treatment (TAILORx) showed that
endocrine therapy alone was noninferior to adjuvant chemotherapy plus endocrine (chemoendocrine) therapy in women with hormone-receptor–
positive, HER2-negative, axillary node–negative
breast cancer and a 21-gene recurrence score of
11 to 25. An exploratory analysis indicated some
benefit of chemotherapy in women 50 years of
age or younger who had a recurrence score of 16
to 25. The trial also showed a low percentage of
women with distant recurrence (3%) at 9 years
with endocrine therapy alone if the recurrence
score was 0 to 15, irrespective of age.7,8
Here, we report the results of secondary
analyses of the TAILORx trial that were designed
to determine whether clinical risk, as assessed
with the use of an algorithm that integrates tumor size and histologic grade, adds prognostic
information to the 21-gene recurrence score and
predictive information regarding the benefit of
chemotherapy. We further examined the relationship between age and the absolute chemotherapy
benefit in women who were 50 years of age or
younger and had a recurrence score of 16 to 25.

of

m e dic i n e

coordinated by the Eastern Cooperative Oncology
Group–American College of Radiology Imaging
Network (ECOG-ACRIN) Cancer Research Group,
as previously described.7 Women who participated
in the trial provided written informed consent,
including a statement of willingness to have
treatment assigned or randomly assigned on the
basis of the 21-gene Oncotype DX recurrencescore assay performed in a central laboratory
(Genomic Health).2
Objective and Definition of Clinical Risk

The standardized definitions for efficacy end
points (STEEP) criteria were used for end-point
definitions.9 One end point was the distant recurrence–free interval, referred to here as distant
recurrence (defined as the time from registration to the date of distant recurrence of breast
cancer, or of death with distant recurrence, if
death was the first manifestation of distant recurrence). Another end point was invasive disease–
free survival, defined as the time from registration to the first event of recurrence (distant or
locoregional), second primary cancer (excluding
nonmelanoma skin cancers), or death without
evidence of recurrence.
A prespecified secondary trial objective was
to determine whether clinical risk, as assessed
with the use of the Adjuvant! algorithm, added
information regarding prognosis for recurrence
and prediction of chemotherapy benefit to that
projected by the Oncotype DX test.7 Classic pathologic information and outcome results were also
used to refine models based on classic information and genomic tests. Adjuvant! is a tool that
uses clinicopathological characteristics to provide
estimates of breast cancer outcomes at 10 years
on the basis of the Surveillance, Epidemiology,
and End Results registry data and treatment effects associated with adjuvant chemotherapy and
endocrine therapy derived by the Early Breast
Cancer Trialists’ Collaborative Group meta-analysis that has been validated in several data sets.10,11
Since Adjuvant! is no longer available for clinical use, we assessed the prognostic information
provided by a binary clinical-risk categorization
based on the Adjuvant! algorithm as used in the
MINDACT (Microarray in Node-Negative Disease
Me thods
May Avoid Chemotherapy) trial.12 A low clinical
Trial Design and Patients
risk was defined as the probability of breast
TAILORx, a prospective clinical trial, was spon- cancer–specific survival at 10 years without syssored by the National Cancer Institute and was temic therapy among more than 92% of women
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with estrogen receptor–positive tumors who received endocrine therapy alone, as projected by
Adjuvant! (version 8.0).11 Clinical risk was defined
as low if the tumor was 3 cm in diameter or
smaller and had a low histologic grade, 2 cm or
smaller and had an intermediate grade, or 1 cm
or smaller and had a high grade; the clinical risk
was defined as high if the low-risk criteria were
not met.
Oversight

This trial was coordinated by the ECOG-ACRIN
Cancer Research Group, with other federally funded groups participating, including the Southwest
Oncology Group, the Alliance for Clinical Trials
in Oncology, NRG Oncology, and the Canadian
Cancer Clinical Trials Network.
The statistical analysis was performed by the
second author, the manuscript was written by
the first author, and a final version of the manuscript, incorporating changes recommended by
the coauthors, was reviewed and approved by all
the authors, who vouch for the accuracy and
completeness of the data and the adherence of
the trial to the protocol (available with the full
text of this article at NEJM.org). No one who is
not an author contributed to the manuscript. No
commercial support was provided in the planning or execution of the trial, but commercial
support was provided by Genomic Health, the
makers of the 21-gene risk score tool, for collection of follow-up information from the treatment sites.
Statistical Analysis

This analysis involved the same intention-to-treat
population previously described.7 Event-free rates
were estimated with the use of the Kaplan–Meier
method, with confidence intervals computed
with log–log transformation and Greenwood’s
variance. Hazard ratios were estimated with the
use of partial likelihood analysis of the Cox
proportional-hazards model, with confidence
intervals symmetric on the log-ratio scale. No
corrections for multiple comparisons were made.

R e sult s
Clinical-Risk Category, 21-Gene Recurrence
Score, and Age

The trial was conducted from April 2006 to October 2010. Of the 9719 women in the trial who
n engl j med 380;25

were included in the primary intention-to-treat
population and who had data that could be
evaluated, information regarding clinical risk,
including both tumor size and histologic grade,
was available for 9427 (97.0%), of whom 6615
(70.2%) had low clinical risk and 2812 (29.8%)
had high clinical risk, with a similar distribution
according to age (≤50 years vs. >50 years). The
recurrence score was high (a score of 26 to 100)
in 589 patients (8.9%) with low clinical risk and
in 770 patients (27.4%) with high clinical risk;
these distributions were also similar according
to age. Endocrine therapy administered to women
who were reported to be premenopausal at registration and to have a recurrence score of 11 or
higher included tamoxifen in 78% of the women
(including 35% who crossed over to an aromatase inhibitor) and ovarian function suppression
alone or in combination with an aromatase inhibitor in 13%; 7% of the women were reported
to receive an aromatase inhibitor, which could
indicate either incorrect reporting of menopausal
status at registration or chemotherapy-induced
menopause.
Clinical-Risk Category and Prognosis

Prognostic information provided by the clinicalrisk category is shown in Figure 1. Estimated
hazard ratios reflect the comparison of the high
clinical-risk group with the low clinical-risk group;
a hazard ratio greater than 1 indicated that a
high clinical risk was prognostic for a higher
event rate. The clinical-risk category added prognostic information regarding distant recurrence
in patients who received endocrine therapy alone
and who had an intermediate recurrence score
of 11 to 25 (hazard ratio, 2.73; 95% confidence
interval [CI], 1.93 to 3.87) and in patients treated
with chemoendocrine therapy who had an intermediate recurrence score (hazard ratio, 2.41;
95% CI, 1.66 to 3.48) or a high recurrence score
of 26 to 100 (hazard ratio, 3.17; 95% CI, 1.94
to 5.19).
In a model of distant recurrence incorporating clinical risk and the recurrence score for the
group of patients with an intermediate recurrence score (6496 patients and 240 distant recurrences), significant prognostic information was
provided by both the clinical-risk level (hazard
ratio for high vs. low risk, 2.42; P<0.001) and the
continuous recurrence score (hazard ratio for an
increase of 1 point in the recurrence score, 1.08;
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High recurrence score (26–100)
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Hazard Ratio for Recurrence,
Second Primary Cancer,
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Hazard Ratio for
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(95% CI)

9427
1572
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96
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273
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Clinical Risk

Figure 1. Effect of Clinical Risk on Prognosis in the Entire Population and Stratified According to Age.
Hazard ratios and 95% confidence intervals (CIs) for a high versus low clinical risk of invasive disease recurrence, second primary can
cer, or death and for distant recurrence (a hazard ratio of >1 indicates a higher event rate with high clinical risk) are shown. There were no
distant recurrences among 64 patients in the subgroup who had a high clinical risk and a low recurrence score. CIs have not been adjusted
for multiple comparisons, and inferences drawn from the intervals may not be reproducible. The size of each square corresponds to the
size of the subgroup; the horizontal lines represent the 95% CI.

P<0.001). Similar findings were noted for rates
of invasive disease–free survival events (defined
as freedom from invasive disease recurrence,
second primary cancer, or death).
An evaluation of the effect of clinical risk on
prognosis with respect to distant recurrence and
invasive disease–free survival, stratified according to age, showed similar prognostic effects in
women older than 50 years of age and in women
50 years of age or younger. Weaker associations
between clinical risk and distant recurrence were
observed in older women who had a low recurrence score (a score of 0 to 10) than among
those who had a higher recurrence score, and no
association was observed in younger women
with a low recurrence score, which may be explained at least partly by the lower event rate
among younger women and the smaller sample size.
2398

n engl j med 380;25

Clinical-Risk Category and Chemotherapy
Benefit

Estimated treatment hazard ratios for 6496
women with an intermediate recurrence score
who were randomly assigned to endocrine or
chemoendocrine therapy are shown in Figure 2.
An estimated hazard ratio of greater than 1 indicates a higher recurrence rate with endocrine
therapy alone than with chemoendocrine therapy. The level of clinical risk was not predictive
of chemotherapy benefit in women who had an
intermediate recurrence score in the entire population, nor in the 4353 women who were older
than 50 years of age or the 2143 women who
were 50 years of age or younger (Fig. 2A). Trends
suggested a chemotherapy benefit in 476 women
who were younger than 50 years of age and had
a recurrence score of 21 to 25, but these trends
did not vary according to clinical risk (Fig. 2B).
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A
Subgroup
All patients
Low clinical risk
High clinical risk
>50 Yr of age
Low clinical risk
High clinical risk
≤50 Yr of age
Low clinical risk
High clinical risk

Hazard Ratio for Recurrence,
Second Primary Cancer,
or Death (95% CI)

No. of
Events

4799
1697

541
270
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111

3173
1180

361
204

80
73

1626
517

180
66

49
38
0.50

1.00

Lower Event
Rate with
Endocrine
Therapy Alone

B
Subgroup
Recurrence score, 11–15
Low clinical risk
High clinical risk
Recurrence score, 16–20
Low clinical risk
High clinical risk
Recurrence score, 21–25
Low clinical risk
High clinical risk

No. of
Distant
Recurrences

No. of
Patients

2.00

4.00

0.50

Lower Event
Rate with
Chemoendocrine
Therapy

Hazard Ratio for Recurrence,
Second Primary Cancer,
or Death (95% CI)

No. of
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No. of
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145

65
14

11
6

671
215

74
26

23
13

319
157

41
26

15
19

Lower Event
Rate with
Endocrine
Therapy Alone

Lower Event
Rate with
Chemoendocrine
Therapy

1.00

Lower Event
Rate with
Endocrine
Therapy Alone

No. of
Patients

0.25 0.50 1.00 2.00 4.00 8.00

Hazard Ratio for
Distant Recurrence
(95% CI)

2.00

4.00

Lower Event
Rate with
Chemoendocrine
Therapy

Hazard Ratio for
Distant Recurrence
(95% CI)

0.25 0.50 1.00 2.00 4.00 8.00

Lower Event
Lower Event
Rate with
Rate with
Chemoendocrine
Endocrine
Therapy
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Figure 2. Effect of Clinical Risk on Prediction of Chemotherapy Benefit.
Panel A shows the effect of clinical risk on prediction of chemotherapy benefit in 6496 women with a recurrence score of 11 to 25 (on a
scale of 0 to 100, with higher scores indicating a worse prognosis or a greater potential benefit from chemotherapy) who were randomly
assigned to endocrine therapy or chemotherapy plus endocrine (chemoendocrine) therapy, and stratified according to age. A total of
4353 women were older than 50 years of age, and 2143 women were 50 years of age or younger. Panel B shows the effect of clinical risk
on prediction of chemotherapy benefit in 2143 women who were 50 years of age or younger and had a recurrence score of 11 to 25. Es
timated hazard ratios are shown for treatment (endocrine vs. chemoendocrine therapy) and 95% CIs for invasive disease–free survival
and distant recurrence (a hazard ratio >1 indicates that chemoendocrine therapy is better). CIs have not been adjusted for multiple com
parisons, and inferences drawn from the intervals may not be reproducible. The size of each square corresponds to the size of the sub
group; the horizontal lines represent the 95% CI.

Age and Chemotherapy Benefit

We further evaluated chemotherapy benefit as a
function of age and menopausal status in 4338
women with a recurrence score of 16 to 25 (Fig. 3).
We found that a chemotherapy benefit was most
evident at 45 years of age in premenopausal
women and waned at younger and older ages
n engl j med 380;25

and with menopause, consistent with an effect
due to chemotherapy-induced premature menopause. Similar results were found when age (without menopausal status) was evaluated as a continuous variable with the use of a natural spline
(Fig. S1 in the Supplementary Appendix, available
at NEJM.org).
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Patients

No. of
Events

203
441
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12
21
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141

69
15

33
5

287
472
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628

34
54
94
109
117

13
19
28
32
31
0.25
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4.00
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(95% CI)
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Figure 3. Effect of Age and Menopausal Status on Chemotherapy Benefit.
Shown is the effect of age and menopausal status on chemotherapy benefit in 4338 women who had a recurrence score of 16 to 25 and
were randomly assigned to endocrine therapy or chemoendocrine therapy. Estimated treatment hazard ratios (endocrine vs. chemoen
docrine therapy) and 95% CIs for rates of distant recurrence at 9 years are shown (a hazard ratio >1 indicates that chemoendocrine ther
apy is better). Menopause was defined as an age of 60 years or older; an age of 45 to 59 years with spontaneous cessation of menses for
at least 12 months before registration; an age of 45 to 59 years with cessation of menses for less than 12 months before registration and
a follicle-stimulating hormone (FSH) level in the postmenopausal range (or >34.4 IU per liter if the institutional range was not available);
prior bilateral oophorectomy; or age younger than 60 years with prior hysterectomy without bilateral oophorectomy and an FSH level
in the postmenopausal range (or >34.4 IU per liter if the institutional range was not available). CIs have not been adjusted for multiple
comparisons, and inferences drawn from the intervals may not be reproducible. The size of each square corresponds to the size of the
subgroup; the horizontal lines represent the 95% CI.

Event Rates at 9 Years, Stratified
According to Age

Kaplan–Meier estimates of event rates at 9 years,
stratified according to age, are shown in Table 1.
In 6469 women who were older than 50 years of
age (two thirds of the trial population), the
mean (±SE) distant recurrence rate at 9 years
was similar, irrespective of use or nonuse of
chemotherapy, in the cohort with an intermediate recurrence score, regardless of whether the
clinical risk was low (4.0±0.7% vs. 3.5±0.6%) or
high (8.3±1.5% vs. 9.3±1.9%). Similar findings
were noted with respect to invasive disease–free
survival.
In 2958 women who were 50 years of age or
younger (one third of the trial population), use
or nonuse of chemotherapy in the group with an
intermediate recurrence score was associated with
similar distant recurrence rates at 9 years if the
clinical risk was low (3.9+1.0% and 4.7±1.0%, re-
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spectively), but distant recurrence rates were lower
with the use of chemotherapy in the group with
high clinical-risk (6.1±1.8% and 12.3±2.4%, respec
tively). Rates of distant recurrence at 9 years were
very low among patients who were 50 years of age
or younger who had a low recurrence score, irrespective of clinical-risk category (≤1.8±0.9%).
Owing to fewer second primary cancers and
deaths, rates of invasive disease–free survival
events were lower among younger women across
all recurrence-score groups than among women
who were older than 50 years of age.
The level of clinical risk also added prognostic information with regard to distant recurrence in
the 1359 women (both younger and older women)
with a high recurrence score who received chemoendocrine therapy. Distant recurrence rates were
also low among 589 women with a high recurrence score and low clinical risk who received
chemotherapy (7.0±2.4% among older women and
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Table 1. Distant or Locoregional Disease Recurrence, Second Primary Cancer, or Death, and Distant Recurrence at 9 Years, According to Use
or Nonuse of Adjuvant Chemotherapy, Stratified According to Age, Recurrence Score, and Clinical Risk (Intention-to-Treat Population).*

Variable

Clinical
Risk

No. of
Patients

Estimated
Probability
of Recurrence,
Second Primary
Cancer, or Death

Hazard Ratio
for Recurrence,
Second Primary
Cancer, or Death
(95% CI)†

percent

Estimated
Probability
of Distant
Recurrence

Hazard Ratio
for Distant
Recurrence
(95% CI)†

percent

6469

Patients >50 yr
Low recurrence score (0–10)
No chemotherapy

High

281

27.2±4.5

No chemotherapy

Low

879

13.3±1.5

High

577

23.2±2.6

No chemotherapy

Low

1605

13.6±1.1

Chemotherapy

High

603

22.6±2.3

Chemotherapy

Low

1568

15.7±1.3

Chemotherapy

High

542

32.1±4.4

Chemotherapy

Low

414

19.3±3.8

2.09 (1.47–2.96)

7.4±3.4

2.20 (0.95–5.08)

2.6±0.8

Intermediate recurrence score
(11–25)
No chemotherapy

1.56 (1.21–2.00)

9.3±1.9

2.61 (1.65–4.11)

3.5±0.6
1.61 (1.27–2.04)

8.3±1.5

2.49 (1.60–3.87)

4.0±0.7

High recurrence score (26–100)
1.85 (1.28–2.66)

19.8±3.9

3.35 (1.82–6.14)

7.0±2.4

2958

Patients ≤50 yr
Low recurrence score (0–10)
No chemotherapy

High

64

9.3±4.5

No chemotherapy

Low

348

13.3±2.3

0.68 (0.24–1.92)

0

0

1.8±0.9

Intermediate recurrence score
(11–25)
No chemotherapy

High

265

19.8±3.0

No chemotherapy

Low

835

17.4±1.8

Chemotherapy

High

252

13.5±3.0

Chemotherapy

Low

791

11.3±1.4

Chemotherapy

High

228

24.0±4.2

Chemotherapy

Low

175

14.8±4.2

1.27 (0.89–1.83)

12.3±2.4

3.06 (1.78–5.25)

4.7±1.0
1.19 (0.76–1.88)

6.1±1.8

2.20 (1.10–4.40)

3.9±1.0

High recurrence score (26–100)
2.27 (1.22–4.19)

15.2±3.3

2.87 (1.23–6.65)

6.2±2.5

*	Plus–minus values are Kaplan–Meier estimates ±SE.
†	A hazard ratio greater than 1 indicates that high clinical risk was prognostic for a higher event rate. Confidence intervals have not been ad
justed, and inferences drawn from the intervals may not be reproducible.

6.2±2.5% among younger women) and were similar to those among older women with a low recurrence score and high clinical risk (7.4±3.4%)
who received endocrine therapy alone. In contrast, among 770 women with a high recurrence
score and high clinical risk, distant recurrence
rates were high among both older and younger women despite the use of chemotherapy
(19.8±3.9% and 15.2±3.3%, respectively).

n engl j med 380;25

Estimation of Chemotherapy Benefit
in Reducing Distant Recurrence at 9 Years

We previously reported that the estimated absolute reduction in the mean (±SE) rate of distant
recurrence at 9 years associated with adjuvant
chemotherapy among women 50 years of age or
younger was 1.6±1.9 percentage points in those
with a recurrence score of 16 to 20 and 6.4± 4.9
percentage points in those with a recurrence
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score of 21 to 25.7 Here, we provide estimates of
the absolute benefit of chemotherapy, further
stratified according to clinical risk (Table 2). In
476 women with a recurrence score of 21 to 25,
the absolute chemotherapy benefit in the subgroup with low clinical risk (6.4±4.9 percentage
points) was similar to that in the subgroup with
high clinical risk (8.7±6.2 percentage points). In
the 886 women with a recurrence score of 16 to
20, there was an estimated chemotherapy benefit with high clinical risk (6.5±4.9%) but not
with low clinical risk (−0.2±2.1%). The sample
size was small in some of the subgroups examined; this contributed to higher standard errors
than estimates for the entire cohort with a recurrence score of 11 to 25.
Prognosis in Women 50 Years of Age
or Younger

Among women who were 50 years of age or
younger, most of whom were premenopausal
and treated with tamoxifen alone or followed
sequentially with an aromatase inhibitor, the distant recurrence rate at 9 years was less than 5%
(≤1.8±0.9%) among those with a low recurrence
score, irrespective of clinical risk, and an intermediate recurrence score with low clinical risk
(4.7±1.0%) (Table 1). In contrast, the rate of distant recurrence at 9 years exceeded 10% among
women with high clinical risk and an intermediate recurrence score who received endocrine
therapy alone (12.3±2.4%) and in those with a
high recurrence score who received chemoendocrine therapy (15.2±3.3%).

Discussion
The recurrence score based on the 21-gene breast
cancer assay provides robust prognostic information regarding distant recurrence2 and predicts
chemotherapy benefit or lack thereof 3,4,7; clinicopathological features provide prognostic information that is complementary to that of this
assay.13-15 The integration of genomic and clinical information may provide a more accurate
estimation of prognosis for individual patients
than could be provided by either the genomic or
clinical information alone.16 Our analysis confirmed that clinical-risk stratification based on
tumor size and histologic grade, when added to
the 21-gene recurrence score, provided prognostic information about recurrence but not
2402
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predictive information regarding chemotherapy
benefit.
Although TAILORx showed that endocrine
therapy was noninferior to chemoendocrine
therapy in women with an intermediate recurrence score (a score of 11 to 25),7 we performed
an exploratory analysis in accordance with recommended guidelines in order to determine
whether any subgroup might derive some benefit
from adjuvant chemotherapy.17 There was a significant interaction between chemotherapy treatment, age (≤50 vs. >50 years) or menopausal
status, and recurrence score, suggesting a modest but clinically meaningful reduction in the
rate of distant recurrence with chemotherapy
among younger or premenopausal women who
had a recurrence score of 16 to 25.7 Similar findings were noted in a population-based study indicating a chemotherapy benefit emerging at a
recurrence score above 15 in women who were
50 years of age or younger and above 25 in
women who were older than 50 years.18
Adjuvant chemotherapy is associated with
nearly twice the reduction in the rate of death
from breast cancer among women younger than
50 years of age as compared with older women1;
this has been attributed to a dual effect, which
includes a direct cytotoxic effect in eradicating
micrometastatic disease and an antiestrogenic
effect from chemotherapy-induced ovarian failure
and premature menopause.19,20 The interaction
among age, recurrence score, and chemotherapy
benefit observed in TAILORx is therefore consistent with the greater treatment effect of adjuvant
chemotherapy in younger women.
Although the potential pitfalls of a subgroup
analysis to identify more effective therapies in
trials with a superiority design have been well
described17 and the exploratory analyses presented here were not adjusted for multiple comparisons, caution is warranted when withdrawing potentially lifesaving therapy on the basis
of a noninferiority trial such as TAILORx, especially when the findings are biologically plausible and supported by population-level data, as
described here. Given the incremental benefits
observed with ovarian suppression plus tamoxifen or an aromatase inhibitor as compared with
tamoxifen alone in premenopausal women21,22
and the low percentage of premenopausal women
who received ovarian suppression in TAILORx,
it is possible that similar incremental benefits

nejm.org

June 20, 2019

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on July 18, 2019. For personal use only. No other uses without permission.
Copyright © 2019 Massachusetts Medical Society. All rights reserved.

n engl j med 380;25

nejm.org

10.1±3.7
11.4±3.8
82
High
Chemotherapy

*	Plus–minus values are Kaplan–Meier estimates ±SE.
†	An estimated hazard ratio of greater than 1 indicates a higher recurrence rate with endocrine therapy alone than with chemoendocrine therapy. Confidence intervals have not been ad
justed, and inferences drawn from the intervals may not be reproducible.

1.86 (0.73–4.74)
5.0±3.0

2.63 (1.14–6.05)
15.8±4.0

26.4±5.4
75
No chemotherapy

161
Low

High

Chemotherapy

19.7±4.5
Low
No chemotherapy

158

16.3±5.8
108
High
Recurrence score of 21–25

Chemotherapy

18.8±5.0

8.7±6.2

3.16 (1.01–9.94)
6.4±4.9
1.38 (0.74–2.57)

5.5±3.0

11.4±3.9

6.5±4.9
4.8±1.5

11.9±3.9
1.68 (0.76–3.72)
19.0±4.5

9.5±1.8
343
Low

High

Chemotherapy

No chemotherapy

107

1.89 (1.18–3.04)
328
Low

19.6±3.1
Recurrence score of 16–20

No chemotherapy

percent

No. of
Patients
Clinical
Risk
Variable

June 20, 2019
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(95% CI)†
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Probability
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Hazard Ratio for
Recurrence, Second
Primary Cancer,
or Death (95% CI)†
Estimated Probability
of Recurrence,
Second Primary
Cancer, or Death

observed in younger women who received chemotherapy and had a recurrence score of 16 to 25
could be achieved with ovarian suppression and
an aromatase inhibitor, as observed in other trials.21,22 This potential is supported by data indicating that a low-to-midrange recurrence score
and high estrogen receptor 1 gene (ESR1) RNA
expression are predictive of benefit from tamoxifen.23,24 For patients who are approaching menopause, a strategy of an initial 2-to-5-year course
of tamoxifen followed by a switch to an aromatase inhibitor at the time of natural menopause
is another reasonable approach.25 This may be
especially true for women with a high ESR1 RNA
score obtained as part of the 21-gene assay,
which is prognostic for late recurrence 5 or more
years after diagnosis and thus may identify
women who are more likely to benefit from continued antiestrogen therapy beyond 5 years.26
Recurrence rates reflect the underlying recurrence risk, the benefit from adjuvant endocrine
therapy, and the benefit from adjuvant chemotherapy, the latter of which has little effect on
nonrecurrence events such as contralateral breast
cancer or second primary cancers.27-29 Estimation of an absolute chemotherapy benefit requires tools to estimate the underlying risk of
recurrence and the treatment effect of chemotherapy, which may vary in magnitude according
to tumor biologic features.
When the recurrence score was further stratified according to clinical risk among TAILORx
patients as described here, there was no evidence
of chemotherapy benefit at 9 years in the subgroup with a low clinical risk and a recurrence
score of 16 to 20, whereas the addition of chemotherapy was associated with lower rates of
distant recurrence ranging from approximately
6 to 8 percentage points among women with a
recurrence score of 21 to 25, irrespective of
clinical risk, and a recurrence score of 16 to 20
with high clinical risk. This absolute chemotherapy benefit is similar to the benefit seen in
unselected patients with node-negative, hormonereceptor–positive breast cancer,30 but it is substantially less than the absolute benefit of 25
percentage points observed in patients with a
high recurrence score of 26 to 100.6 The treatment effect associated with chemotherapy in this
subgroup is similar to that observed with ovarian suppression plus an aromatase inhibitor as
compared with tamoxifen.21,22 The level of clini-

Table 2. Recurrence, Second Primary Cancer, or Death, and Distant Recurrence at 9 Years, According to Use or Nonuse of Adjuvant Chemotherapy in Women Younger than 50 Years of Age,
Stratified According to Recurrence Score and Clinical Risk (Intention-to-Treat Population).*
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cal risk also added prognostic information for
women with a high recurrence score who were
receiving chemoendocrine therapy, irrespective of
age, and thus could be used to identify patients
with very high risk for whom testing of new therapeutic approaches in clinical trials is warranted.
In conclusion, binary clinical-risk stratification based on tumor size and histologic grade
added prognostic information to the 21-gene
recurrence score, but not prediction of a large
chemotherapy benefit. The addition of this information enabled more precise identification of
subgroups of younger women who may derive
some benefit from more effective antiestrogen
therapy than a course of tamoxifen.
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